Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0000 |
Ask | 2.7500 |
Strike | 77.50 |
Expiry date | 2024-01-19 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 918 |
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise
Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.